EUVIMEDEUVIMED entdecken
Zurückgezogene PublikationOpen Access

Universal theranostic CRISPR/Cas13a RNA-editing system for glioma

Ye Wu, Yunfei Wang, Junhu Zhou, Jianhao Wang, Qi Zhan, Qixue Wang, Eryan Yang, Weili Jin, Fei Tong, Jixing Zhao, Biao Hong, Junrui Liu und 1 weitere

Theranostics · 2023

DOI: 10.7150/thno.84429 ↗

Kurz gefasst

Zurückgezogene Publikation in der Zeitschrift Theranostics, 2023. Verfasst von Ye Wu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Neurological Institute, Tianjin Medical University General Hospital, Key Laboratory of Post-neurotrauma Neuro-repair and Regeneration in Cent…. Hauptthemen laut MEDLINE: Clustered Regularly Interspaced Short Palindromic Repeats, Glioma. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The CRISPR/Cas13a system offers the advantages of rapidity, precision, high sensitivity, and programmability as a molecular diagnostic tool for critical illnesses. One of the salient features of CRISPR/Cas13a-based bioassays is its ability to recognize and cleave the target RNA specifically. Simple and efficient approaches for RNA manipulation would enrich our knowledge of disease-linked gene expression patterns and provide insights into their involvement in the underlying pathomechanism. However, only a few studies reported the Cas13a-based reporter system for in vivo molecular diagnoses.

Methods

A tiled crRNA pool targeting a particular RNA transcript was generated, and the optimally potential crRNA candidates were selected using bioinformatics modeling and in vitro biological validation methods. For in vivo imaging assessment of the anti-GBM effectiveness, we exploited a human GBM patient-derived xenograft model in nude mice.

Results

The most efficient crRNA sequence with a substantial cleavage impact on the target RNA as well as a potent collateral cleavage effect, was selected. In the xenografted GBM rodent model, the Cas13a-based reporter system enabled us in vivo imaging of the tumor growth. Furthermore, systemic treatments using this approach slowed tumor progression and increased the overall survival time in mice.

Conclusions

Our work demonstrated the clinical potential of a Cas13a-based in vivo imaging method for the targeted degradation of specific RNAs in glioma cells, and suggested the feasibility of a tailored approach like Cas13a for the modulation of diagnosis and treatment options in glioma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clustered Regularly Interspaced Short Palindromic RepeatsGliomaHumansAnimalsMiceMice, NudePrecision MedicineCRISPR-Cas SystemsRNA

Stichwörter der Autor:innen

CRISPR/Cas13aGlioblastomaIDH1anti-tumor therapyin vivo detection

Substanzen

RNA

Autor:innen und Institutionen

  • Tianjin Neurological Institute, Tianjin Medical University General Hospital, Key Laboratory of Post-neurotrauma Neuro-repair and Regeneration in Central Nervous System, Ministry of Education, Tianjin City, Tianjin 30005…
  • Department of Dermatovenereology, Tianjin Medical University General Hospital, Tianjin 300052, China.
  • Tianjin Key Laboratory of Composite and Functional Materials, School of Materials Science and Engineering, Tianjin University, Tianjin, China.
  • College of Pharmacy, Kunming Medical University, Yunnan, China.

Zitieren

APA

Wu, Y., Wang, Y., Zhou, J., Wang, J., Zhan, Q., Wang, Q., Yang, E., Jin, W., Tong, F., Zhao, J., Hong, B., Liu, J., & Kang, C. (2023). Universal theranostic CRISPR/Cas13a RNA-editing system for glioma. Theranostics. https://doi.org/10.7150/thno.84429

Vancouver

Wu Y, Wang Y, Zhou J, Wang J, Zhan Q, Wang Q, et al. Universal theranostic CRISPR/Cas13a RNA-editing system for glioma. Theranostics. 2023. doi:10.7150/thno.84429

BibTeX
@article{Wu2023,
  author = {Wu, Ye and Wang, Yunfei and Zhou, Junhu and Wang, Jianhao and Zhan, Qi and Wang, Qixue and Yang, Eryan and Jin, Weili and Tong, Fei and Zhao, Jixing and Hong, Biao and Liu, Junrui and Kang, Chunsheng},
  title = {Universal theranostic CRISPR/Cas13a RNA-editing system for glioma},
  journal = {Theranostics},
  year = {2023},
  doi = {10.7150/thno.84429}
}
Kostenlos starten →